Table 1 Demographics of study participants
Demographics (n = 1203) | Number | Percentage |
|---|---|---|
Age (years) | 62.5 ± 13.1 (Range) | – |
Gender | ||
 Male | 571 | 47.5 |
 Female | 632 | 52.5 |
Education | ||
 None | 9 | 6.6 |
 Primary | 595 | 49.5 |
 Secondary | 400 | 33.3 |
 Tertiary | 129 | 10.7 |
Income | ||
 None | 339 | 28.2 |
 Pensioner | 631 | 52.5 |
 $5000 - $10,000 TTD | 196 | 16.3 |
  > $10,000 TTD | 37 | 3.1 |
Ethnicity | ||
 South Asian | 690 | 57.4 |
 Caribbean Black | 379 | 1.5 |
 Interracial and/or other | 134 | 1.1 |
Comorbidity | ||
 CVD (definite) | 1085 | 90.2 |
 USA | 612 | 56.4 |
 NSTE-ACS | 244 | 22.5 |
 STE-ACS | 229 | 21.1 |
 PCI | 276 | 25.4 |
 CABG | 414 | 38.2 |
 HF-rEF | 687 | 63.3 |
 HF-pEF | 233 | 21.5 |
 AF | 92 | 7.6 |
 CIEDs | 49 | 4.1 |
 DM | 576 | 47.9 |
 HTN | 860 | 71.5 |
 HLD | 614 | 51.0 |
 CVE | 139 | 11.6 |
 CKD | 101 | 8.4 |
 COPD | 69 | 5.7 |
 PVD | 115 | 9.6 |
Cardiovascular Medications | ||
 Aspirin | 826 | 68.7 |
 Clopidogrel | 382 | 31.8 |
 Ticagrelor | 27 | 2.2 |
 VKA | 112 | 9.3 |
 DOAC | 14 | 1.2 |
 ACEi | 505 | 42.0 |
 ARB | 150 | 12.5 |
 BB | 538 | 44.7 |
 Statin | 644 | 53.5 |
 MRA | 61 | 5.1 |
 Loop diuretics | 211 | 17.5 |
 Ivabradine | 88 | 7.3 |
 CCB | 204 | 17.0 |
 Nitrates | 282 | 23.4 |
 Trimetazidine | 313 | 26.0 |
 Analgesics | 23 | 1.9 |